Back to RA CAPITAL MANAGEMENT, L.P. RA CAPITAL MANAGEMENT, L.P.

ASNDASND

Showing 8 of 31 quarters

Position history for RA CAPITAL MANAGEMENT, L.P.RA CAPITAL MANAGEMENT, L.P.'s holdings in <![CDATA[ASCENDIS PHARMA A/S]]>

As of its Q1 2026 13F, RA Capital Management held 10,281,496 shares of ASND (<![cdata[ascendis Pharma A/S]]>), worth $2.4B. RA Capital Management's 13F filings listed ASND from Q4 2018 to Q1 2026, 30 quarterly filings. ASND was 24.9% of RA Capital Management's reported 13F portfolio.

Final Value

$0

Final Shares

0

Total Value Change

-$1.4B

Total Shares Change

-9.7M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$266.72
0
2026-Q1
Unchanged
10.3M
0.0%
$2.4B24.9%$228.73
0
2025-Q4
Unchanged
10.3M
0.0%
$2.2B22.5%$213.24
0
2025-Q3
Unchanged
10.3M
0.0%
$2B25.2%$198.81
0
2025-Q2
Unchanged
10.3M
0.0%
$1.8B29.9%$172.60
0
2025-Q1
Increased
10.3M
+1.7%
$1.6B26.8%$155.86
63
2024-Q4
Increased
10.1M
+4.1%
$1.4B18.5%$137.67
65
2024-Q3
Decreased
9.7M
-3.9%
$1.4B16.7%$149.31
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used